VEGFA, VEGFR1, VEGFR2 serum and cerebrospinal fluid concentration in patients with acute leukemia
| Autor: | E. I. Zakharko, V. N. Dvirnyk, Yu. A. Chabaeva, D. G. Drokova, E. B. Rybkina, K. A. Lavrishinets, A. V. Bulgakov, M. N. Panasenko, Z. T. Fidarova, I. A. Lukianova, O. A. Aleshina, S. M. Kulikov, T. V. Gaponova, V. V. Troitskaya, E. N. Parovichnikova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Онкогематология, Vol 19, Iss 2, Pp 34-45 (2024) |
| Druh dokumentu: | article |
| ISSN: | 1818-8346 2413-4023 |
| DOI: | 10.17650/1818-8346-2024-19-2-34-45 |
| Popis: | Background. Vascular endothelial growth factor A (VEGFA) is one of the most important factors for regulation of hematopoietic stem cells differentiation. It is involved in leukemogenesis and central nervous system (CNS) damage in acute leukemia. According to the literature, the VEGFA production by blast cells is increased, but the values of serum concentration and the associations with CNS involvement are contradictory.Aim. evaluate the VEGFA, VEGFR1, VEGFR2 concentration in serum and cerebrospinal fluid of patient with different types of acute leukemia in disease onset and during treatment.Materials and methods. The concentration of VEGFA in serum and cerebrospinal fluid was studied in 74 primary patients with acute leukemia. The comparison group consisted of 67 healthy donors. VEGFR1, VEGFR2 were studied in serum and cerebrospinal fluid in 34 patients at the onset of the disease. The comparison group consisted of 10 healthy donors. For the analysis, an enzyme immunoassay was used on a semi-automatic Personal Lab analyzer (Adaltis) and Affymetrix eBioscience human VEGF-A Platinum ELISA reagents.Results. Serum VEGFA concentration was statistically significantly lower in acute leukemia patients than that of donors (median 149.78 and 432.19 pg/ml respectively; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|